© 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. This is the protocol for a review and there is no abstract. The objectives are as follows: To determine the diagnostic test accuracy (DTA) of the 18F PET ligands for Aβ (18F-Florbetapir, 18F-Florbetaben, and 18F-Flutemetamol) as the index tests for detecting participants with mild cognitive impairment (MCI) at baseline who would clinically progress to Alzheimer's disease dementia (ADD), or other forms of non-ADD, or any form of dementia at follow-up. To investigate the heterogeneity of the DTA in the included studies, we will evaluate the spectrum of people, referral centres, clinical criteria of MCI, 18F PET ligands for Aβ (18F-Florbetapir, 18F-Florbetaben, and 18F-Flutemetamol) techniques, reference standards used, duration of follow-up, aspects of study quality, and conflicts of interest.
|Journal||Cochrane Database of Systematic Reviews|
|Publication status||Published - 30 May 2016|
Martínez, G., Flicker, L., Vernooij, R. W., Fuentes Padilla, P., Zamora, J., Roqué i Figuls, M., Urrútia, G., & Bonfill Cosp, X. (2016). 18F PET ligands for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews, 2016(5), [CD012216]. https://doi.org/10.1002/14651858.CD012216